A Look Behind the Curtain - Research on PetroTerra, Kirin International Holdings, Force Protection Video Equipment, Black Stallion Oil & Gas, and PharmaCyte Biotech

NEW YORK, NY / ACCESSWIRE / October 22, 2015 / Moments ago, ACI Association released new research updates concerning several important developing situations including the following equities: Petroterra Corp (OTC: PTRA), Kirin International Holding Inc. (OTC: KIRI), Force Protection Video Equipment Corp (OTC: FPVD), Black Stallion Oil and Gas Inc. (OTC: BLKG), and Pharmacyte Biotech Inc. (OTC: PMCB). ACI Association provides a single unified platform for investors to hear about what matters. The full research reports are being made available to the public on a complimentary basis.

To access our full PDF reports for free, please visit the links below.

============

Full PDF DOWNLOAD Links

(You may have to copy and paste the links into your browser)

============

Highlights from today's reports include:

On Tuesday, October 20, 2015, the U.S. markets finished marginally lower as Nasdaq ended at 4,880.97, down 0.50%, Dow Jones declined 0.08%, to finish the day at 17,217.11, and the S&P closed at 2,030.77, down 0.14%.

- Colorado-based Petroterra Corp's stock edged higher by 2.25% to close Tuesday's session at USD 0.91 while the broad market ended in the red. On October 14, 2015, PetroTerra Corp. announced the appointment of Roy A. Moore as Company Landman pursuant to an independent contractor agreement with RAM Land Services, LLC (RAM) - a Central Utah based provider of full, turnkey land services, founded by Mr. Moore in 2012. As per the release, Roy has also served as Landman and seismographic coordinator in Wolverine Gas & Oil for eight years, wherein he was responsible for lease buying, mineral title research/ownership reports, lease take-off research and specialized assignments. PetroTerra's CEO, John Barton, stated that Roy's local experience in land and lease matters in central Utah will be of great value in the execution of PetroTerra's initial exploration program. He added, "In addition to his detailed knowledge of local oil & gas operations, Roy has a wide-ranging set of skills he has gained from his time at RAM and at Wolverine Gas & Oil." The company's shares oscillated between USD 0.87 and USD 0.99. The oil and gas exploration and development company's stock recorded a trading volume of 0.42 million shares, which was significantly above its 50-day daily average volume of 0.14 million shares. While the stock has surged 109.20% in the past one month and 62.50% in the last three months, the stock has seen a dip recently with the shares retreating 8.45% over the last three days and 38.10% in the past one week. Moreover, the company is trading above its 50-day moving average of $0.52 and has a RSI (14-day) of 56.66.

- The stock of Kirin International Holding Inc. jumped 20.80% to close at USD 6.04 in the last session. A total of 0.23 million shares were traded during the session, much higher than its 150-day daily average volume of 0.05 million shares. On September 10, 2015, Kirin International Holdings Inc. (Kirin) announced the execution of a Memorandum of Understanding ("MOU") with Jasper Lakes Holdings Limited and Crestlake Holdings Limited, to acquire a 100% interest in Wuhan Yangtze River New Port Logistics Co. (Wuhan Co.). Wuhan Co. owns Wuhan Yangtze River Newport Logistics Center (Logistics Center), which is an extensive complex located in the Hubei Province - a major transportation hub in China. As per the release, Kirin shall acquire 51% and 49% equity in the Logistics Center from Jasper Lake and Crestlake, respectively, by issuing 166 million shares valued at $10 each, based on an independent valuation of $1.66 billion of Logistics Center. Jianfeng Guo, CEO, Director and President of Kirin, stated that together with its growing residential property portfolio, the new asset would allow the Company to increase its presence across China, and in the international arena. The stock has recently moved up with shares advancing 42.12% over the last one week and 108.28% and in the past one month. Moreover, over the last three months, the stock has added 308.11% and in the past six months, the shares have grown by a whopping 2,306.37%. Further, the company is trading at a price to earnings ratio of 45.05x. The price to book ratio of 2.1x compares to a historical P/B of 0.02x. Furthermore, Kirin International Holding Inc. is trading above its 50-day and 200-day moving averages of $2.80 and $1.25, respectively.

- Force Protection Video Equipment Corp's stock followed the broad market trend, declining 7.65% to close Tuesday's session at USD 1.57, thereby snapping its 6-day winning streak. The video camera-manufacturer's shares fluctuated in the range of USD 1.55 and USD 1.80. A total of 0.44 million shares exchanged hands, which surpassed its 50-day daily average volume of 0.06 million shares. Force Protection Video Equipment Corp.’s (Force Protection) body-worn high definition (HD) camera, LE10, showcased superior performance than its competitors in a 30-day test and evaluation by a Northern California Police Department, as reported by Business Wire on September 17, 2015. Based on the positive feedback over the size, video quality and pricing, Force Protection has received multiple reorders for LE10 from Police Departments in Tennessee and District Attorneys' Offices in Louisiana. LE10, which is rich with features such as still picture ability 8MP, WIFI, 4x zoom and audio recording, does not require special software or expensive storage contracts and has the ability to download the video files quickly into a standard law enforcement case file, enabling agencies to store it securely. Over the last three days, Force Protection Video Equipment Corp's shares have declined by 2.48% while in the past one week the stock has seen a price appreciation of 7.53%. Additionally, the stock is trading below its 50-day moving average of $1.79. Moreover, Force Protection Video Equipment Corp’s stock has a RSI (14-day) of 45.42.

- Black Stallion Oil and Gas Inc.'s stock continued its downward momentum as it slipped 1.15% to close Tuesday's session at USD 0.82. The company's shares changed hands in the range of USD 0.71 and USD 0.83. The stock's trading volume of 0.19 million was below its 52-week average volume of 0.24 million. On October 07, 2015, Black Stallion Oil & Gas, Inc. (Black Stallion) announced the acquisition of remaining 50% working stake in the 12,233-acre Woodrow Prospect in Northwest Montana, based within the Alberta Basin Bakken fairway. Following the latest deal, the company now owns a 100% working interest in the Woodrow Prospect. The Woodrow Prospect offers multiple opportunities for successful Oil & Gas production across multiple potential targets, as reported in June 2014's NI 51-101 report by B.L. Whelan, P. Geo on the Woodrow Prospect. The report also recommended an exploration program in the prospect in order to determine the potential hydrocarbon content of various formations. In September 2015, Black Stallion finalized a Master Services Consulting Agreement with Sproule Associates Ltd, in connection with the firm launching a four-phase work plan on the prospect. The company expects Phase I to be concluded by end of this month. Over the last one week, Black Stallion Oil and Gas Inc.'s shares have declined by 17.75% and in the past one month the stock has lost 36.92%. However, over the last six months the stock has witnessed significant upside of 64.00%. Despite the price decline in the last few sessions, the company's shares are trading above their 50-day and 200-day moving averages of $0.50 and $0.52, respectively.

- Pharmacyte Biotech Inc.'s stock declined 1.04% to close Tuesday's session at USD 0.11 as the healthcare sector ended lower for the day. The share price vacillated between USD 0.11 and USD 0.12. The stock's trading volume of 1.91 million shares was well above its 50-day daily average volume of 1.79 million shares. On October 19, 2015, the clinical-stage biotechnology company, PharmaCyte Biotech, Inc. (PharmaCyte), announced that it is going to conduct a clinical trial for pancreatic cancer treatment (Cell-in-a-Box(R) capsules + low-doses of ifosfamide chemotherapy) in the US, along with some additional study sites in Europe and Australia. The decision for conducting it in the US was made after PharmaCyte's pancreatic cancer treatment showcased better results in early phase trials, compared to Celgene's Abraxane(R)+gemcitabine, which is considered to be the "gold standard" for the treatment of patients with advanced pancreatic cancer, in these sites. The trial, if successful in these countries, would accelerate the review process by drug regulatory authorities for marketing approval of the treatment. Two of the world's leading Clinical Research Organizations (CRO), Translational Drug Development (TD2) and Clinical Network Services (CNS) will be working together on this clinical trial. Over the last three days Pharmacyte Biotech Inc.'s shares have declined by 3.39% and in the past one week the stock has moved down 6.94%. However, over the last one month and previous three months, the stock has seen a price appreciation of 37.35% and 3.64%, respectively. In addition, the biotechnology company's P/B ratio of 12.2x is at a discount to its historical P/B multiple of 19.15x.

--

About ACI Association:

Active Charter Investors Association ("ACI Association") produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. ACI Association has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

ACI Association has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer"). The Reviewer has reviewed and revised the content, as necessary, based on sound investment judgment and publicly available information which is believed to be reliable. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer (collectively referred to as the "Production Team") in any way. The Production Team is compensated on a fixed monthly basis and do not hold any positions of interest in any of the securities mentioned herein. The information in this release has been sourced from a third party data base.

NO WARRANTY

ACI Association, the Author and the Reviewer (collectively referred to as the "Publishers") are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by the Publishers whatsoever for any direct, indirect or consequential loss arising from the use of this document. The Publishers expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, the Publishers do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither ACI Association nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.aciassociation.com/.

RESTRICTIONS

ACI Association is not available to residents of Belarus, Cuba, Canada, Iran, North Korea, Sudan, Syria or Somalia.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

E-mail: media@aciassociation.com

Phone: 1-888-675-6291 (Market Hours)

SOURCE: ACI Association